Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC) | ANNALS OF ONCOLOGY |